Vimal Mehta; President, Chief Executive Officer, Director; BioXcel Therapeutics Inc Richard Steinhart; Chief Financial Officer, Senior Vice President; BioXcel Therapeutics Inc Vincent O’Neill; Executive Vice…
November 14, 2024
– 108 patients have completed 1-year of treatment in 1-year open-label extension (OLE) trial – – Vocal biomarker speech latency data from RECOVER trial reinforce…
FREMONT, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) — ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology,…
FREMONT, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) — ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology,…
BioXcel Therapeutics, Inc. (BTAI) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.50. This…
November 14, 2024
BioXcel Therapeutics Reports Third Quarter 2024 Financial Results
Advancing two pivotal Phase 3 trials of BXCL501 for acute treatment of agitation associated with bipolar disorders, schizophrenia, and Alzheimer’s dementia Conference call set for…
November 12, 2024
Here’s Why Acadia Pharmaceuticals (ACAD) is a Strong Momentum Stock
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. While you may have an investing…
November 12, 2024
Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia
– 108 patients have completed 1-year of treatment – – Brilaroxazine is generally well tolerated to date in patients with acute and stable schizophrenia – –…
Raising Full-Year 2024 Revenue Guidance to $40-41 Million and Initiating Profitability Guidance BURLINGTON, Mass. and JERUSALEM, Israel, Nov. 12, 2024 (GLOBE NEWSWIRE) — BrainsWay Ltd….
First patient randomized in SERENITY At-Home trial of BXCL501 for acute treatment of agitation associated with bipolar disorders or schizophrenia Received FDA feedback on protocol…
November 12, 2024
CING: Third Quarter Results
By John Vandermosten, CFA NYSE:CING READ THE FULL CING RESEARCH REPORT Cingulate, Inc. (NASDAQ:CING) reported third quarter results on November 7th, 2024. No revenues were…
ADELAIDE, Australia and CAMBRIDGE, Mass., Nov. 08, 2024 (GLOBE NEWSWIRE) — Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric…